shares of Sesen Bio Inc (SESN) on
Sesen Bio, Inc. engages in designing, engineering, and developing of targeted protein therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 17 full-time employees. The firm is focused on developing antibody-drug conjugate (ADC) therapies for the treatment of cancer. Its product pipeline includes Vicinium, Vicinium in combination with checkpoint inhibator, durvalumab, and VB6-845d. The Company’s lead program, Vicinium, is a fusion protein in Phase III development for the treatment of non-muscle invasive bladder cancer (NMIBC). The company targets epithelial cell adhesion molecule (EpCAM) antigens on the surface of tumor cells to deliver a potent cytotoxin, Pseudomonas Exotoxin A (ETA) directly to cancer cells.